Free Trial
NASDAQ:AGIO

Agios Pharmaceuticals (AGIO) Stock Price, News & Analysis

Agios Pharmaceuticals logo
$28.44 +1.04 (+3.80%)
Closing price 04:00 PM Eastern
Extended Trading
$28.06 -0.38 (-1.32%)
As of 04:41 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Agios Pharmaceuticals Stock (NASDAQ:AGIO)

Key Stats

Today's Range
$26.81
$28.65
50-Day Range
$27.40
$35.54
52-Week Range
$26.66
$62.58
Volume
955,571 shs
Average Volume
704,951 shs
Market Capitalization
$1.63 billion
P/E Ratio
2.51
Dividend Yield
N/A
Price Target
$56.57
Consensus Rating
Moderate Buy

Company Overview

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Remove Ads

Agios Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

AGIO MarketRank™: 

Agios Pharmaceuticals scored higher than 85% of companies evaluated by MarketBeat, and ranked 150th out of 927 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Agios Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Agios Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

  • Read more about Agios Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Agios Pharmaceuticals are expected to grow in the coming year, from ($6.85) to ($5.79) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Agios Pharmaceuticals is 2.51, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 22.55.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Agios Pharmaceuticals is 2.51, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 23.12.

  • Price to Book Value per Share Ratio

    Agios Pharmaceuticals has a P/B Ratio of 1.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Agios Pharmaceuticals' valuation and earnings.
  • Percentage of Shares Shorted

    6.16% of the float of Agios Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Agios Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Agios Pharmaceuticals has recently decreased by 13.71%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Agios Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Agios Pharmaceuticals does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.16% of the float of Agios Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Agios Pharmaceuticals has a short interest ratio ("days to cover") of 4.3.
  • Change versus previous month

    Short interest in Agios Pharmaceuticals has recently decreased by 13.71%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    Agios Pharmaceuticals has a news sentiment score of 0.97. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 4 news articles for Agios Pharmaceuticals this week, compared to 5 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Agios Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $90,233.00 in company stock.

  • Percentage Held by Insiders

    Only 4.93% of the stock of Agios Pharmaceuticals is held by insiders.

  • Read more about Agios Pharmaceuticals' insider trading history.
Receive AGIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Agios Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

AGIO Stock News Headlines

Here’s How to Claim Your Stake in Elon’s Private Company, xAI
Even though xAI is a private company, tech legend and angel investor Jeff Brown found a way for everyday folks like you… To partner with Elon on what he believes will be the biggest AI project of the century… Starting with as little as $500.
Agios to Present at Upcoming Investor Conferences
See More Headlines

AGIO Stock Analysis - Frequently Asked Questions

Agios Pharmaceuticals' stock was trading at $32.86 at the beginning of the year. Since then, AGIO shares have decreased by 13.5% and is now trading at $28.44.
View the best growth stocks for 2025 here
.

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) released its earnings results on Thursday, February, 20th. The biopharmaceutical company reported ($1.74) EPS for the quarter, missing analysts' consensus estimates of ($1.69) by $0.05. Agios Pharmaceuticals had a net margin of 1,845.92% and a negative trailing twelve-month return on equity of 2.51%.

Shares of AGIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Agios Pharmaceuticals investors own include Waste Connections (WCN), American Water Works (AWK), DiamondRock Hospitality (DRH), The RMR Group (RMR), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Voyager Therapeutics (VYGR).

Company Calendar

Last Earnings
2/20/2025
Today
4/02/2025
Next Earnings (Estimated)
5/01/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:AGIO
Fax
N/A
Employees
390
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$56.57
High Stock Price Target
$75.00
Low Stock Price Target
$46.00
Potential Upside/Downside
+102.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.56
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
2.47
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$673.72 million
Net Margins
1,845.92%
Pretax Margin
1,967.15%

Debt

Sales & Book Value

Annual Sales
$36.50 million
Price / Cash Flow
N/A
Book Value
$27.02 per share
Price / Book
1.04

Miscellaneous

Free Float
54,471,000
Market Cap
$1.60 billion
Optionable
Optionable
Beta
0.90

Social Links

20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?

Get This Free Report

This page (NASDAQ:AGIO) was last updated on 4/2/2025 by MarketBeat.com Staff
From Our Partners